The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma

GSK2190915, a potent 5‐lipoxygenase‐activating protein inhibitor, prevents the synthesis of leukotrienes and 5‐oxo‐6,8,11,14‐eicosatetraenoic acid (5‐oxo‐ETE).

[1]  Jilly F. Evans,et al.  Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. , 2010, European journal of pharmacology.

[2]  Jilly F. Evans,et al.  5-Lipoxygenase-activating Protein (FLAP) Inhibitors Are Superior To 5-lipoxygenase (5-LO) Inhibitors For Inhibition Of Leukotriene Synthesis In Rat Lung , 2010, ATS 2010.

[3]  J. Rokach,et al.  5-Oxo-ETE and the OXE receptor. , 2009, Prostaglandins & other lipid mediators.

[4]  L. Boulet,et al.  Single-dose desloratadine and montelukast and allergen-induced late airway responses , 2009, European Respiratory Journal.

[5]  E. Gelfand,et al.  The role of leukotriene B(4) in allergic diseases. , 2008, Allergology international : official journal of the Japanese Society of Allergology.

[6]  E. Gelfand,et al.  The Role of Leukotriene B4 in Allergic Diseases. , 2008, Allergology international : official journal of the Japanese Society of Allergology.

[7]  A. Woodcock,et al.  Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. , 2007, American journal of respiratory and critical care medicine.

[8]  J. Janssens,et al.  [Leukotriene-modifiers in asthma treatment]. , 2006, Revue medicale suisse.

[9]  L. Karlsson,et al.  Leukotriene B4 Receptors BLT1 and BLT2: Expression and Function in Human and Murine Mast Cells , 2006, The Journal of Immunology.

[10]  A. Baatjes,et al.  Expression of functional cysteinyl leukotriene receptors by human basophils. , 2005, The Journal of allergy and clinical immunology.

[11]  J. Lötvall,et al.  Differential effects of fluticasone and montelukast on allergen‐induced asthma , 2005, Allergy.

[12]  Jilly F. Evans.  The Cysteinyl Leukotriene (CysLT) Pathway in Allergic Rhinitis , 2005 .

[13]  M. Curtis,et al.  Cysteinyl‐leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl leukotrienes , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  P. O'Byrne,et al.  Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. , 2002, American journal of respiratory and critical care medicine.

[15]  P. Barnes,et al.  The allergen challenge , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  D. Cockcroft.  Allergen-induced increase in nonallergic airway responsiveness: a citation classic revisited. , 2000, Canadian respiratory journal.

[17]  Jilly F. Evans,et al.  Characterization of the human cysteinyl leukotriene CysLT1 receptor , 1999, Nature.

[18]  Diamant,et al.  The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[19]  P. O'Byrne,et al.  Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. , 1997, Thorax.

[20]  P. Barnes,et al.  Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. , 1996, Thorax.

[21]  P. Sterk,et al.  The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. , 1995, The Journal of allergy and clinical immunology.

[22]  G. Cieslewicz,et al.  [Course of non-specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma]. , 1995, Pneumonologia i alergologia polska.

[23]  A. Williams,et al.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. , 1994, Thorax.

[24]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[25]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[26]  J. B. Rasmussen.  Late airway response increases at repeat allergen challenge , 1991, Allergy.

[27]  K. P. Hui,et al.  Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. , 1991, Thorax.

[28]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.